• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ATENOLOL Drug Record

  • Summary
  • Interactions
  • Claims
  • ATENOLOL chembl:CHEMBL24 Approved

    Alternate Names:

    ESATENOLOL
    ATENIX-100
    IBINOLO
    VASATEN
    TENORMIN 25
    ATENAMIN
    ANTIPRESSAN
    TENORMIN
    TENORMIN L.S.
    TOTAMOL
    UNIBLOC
    ATENIX-25
    ATENIX-50
    ATENOLOL
    C07AB03
    ICI 66082
    KENTOL
    ICI-66082
    TREDOL
    XATEN
    ATENOL FECOFAR
    2-(P-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ACETAMIDE
    PREMORINE
    TENORMIN®
    PRINORM
    LOTENAL
    HIPRES
    ATEROL
    ATENOL TROM
    ATENOLOLUM [INN-LATIN]
    TENOBLOCK
    DURAATENOLOL
    ATENOLOL [USAN:BAN:INN:JAN]
    BLOCOTENOL
    ATENOL AL
    EVITOCOR
    SERTEN
    NORMITEN
    TENOBLOC
    ATENOL VON CT
    NORMALOL
    ATENOLOL (JAN/USP)
    FARNORMIN
    ATENBLOCK
    TENOPRIN
    ATENIL
    UNILOC
    WESIPIN
    ATENOLIN
    ATENOL COPHAR
    LOTEN
    SELES BETA
    TENORETIC
    ATENOL QUESADA
    SCHEINPHARM ATENOL
    ATENOL-WOLFF
    JUVENTAL
    TENORMINE
    ATENOL GADOR
    BETABLOK
    VASCOTEN
    ATENOLOLUM
    NOTEN
    HYPOTEN
    BETATOP GE
    CARDIOPRESS
    FELO-BITS
    COROTENOL
    DURATENOL
    ATENOMEL
    ATENOL HEUMANN
    BETACARD
    ATENOL-RATIOPHARM
    ATENOL PB
    BLOKIUM
    ANSELOL
    ATENOL 1A PHARMA
    TENSIMIN
    ATENOL ATID
    ALTOL
    SERVITENOL
    PANAPRES
    INTERNOLOL
    ATECARD
    ATENOL NORDIC
    APO-ATENOLOL
    TENIDON
    MYOCORD®
    ATENOL CT
    AIRCRIT
    ATENOL GNR
    ALINOR
    STERMIN
    TENOLOL
    1-P-CARBAMOYLMETHYLPHENOXY-3-ISOPROPYLAMINO-2-PROPANOL
    TENORMINE [FRENCH]
    SELOBLOC
    CARDAXEN
    ATENI
    ATENOL ACIS
    MYOCORD
    ATENOL GENERICON
    ATENDOL
    ATENET
    PRENOLOL
    4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)BENZENEACETAMIDE
    ATEHEXAL
    LO-TEN
    PLENACOR
    BETASYN
    ATENOL-MEPHA
    ORADAY
    ATEREAL
    ATENOL NM PHARMA
    PRENORMINE
    ATENOL TIKA
    ORMIDOL
    ATENOL MSD
    JENATENOL
    ATENOL STADA
    ATCARDIL
    NORMITEN®
    CUXANORM
    VERICORDIN
    rxcui:1202
    drugbank:00335
    chemidplus:29122-68-7
    pubchem.compound:2249
    chembl:CHEMBL24

    Drug Info:

    Year of Approval 1981
    Drug Class antihypertensive agents
    Drug Class anti-arrhythmia agents
    FDA Approval 1981
    Drug Class small molecule
    Drug Indications Antihypertensive Agents
    Drug Indications Anti-Arrhythmia Agents
    (4 More Sources)

    Publications:

    Iniesta R et al., 2019, Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals., Hypertension
    Kayser et al., 1989, Changes in serum phosphate during beta-blockade in healthy men are not due to changes in the renal handling of phosphate., J. Intern. Med.
    Liljedahl U et al., 2004, Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment., J Hypertens
    Filigheddu F et al., 2010, Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension., Pharmacogenomics
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem
    Rau T et al., 2012, Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients., Clin Pharmacol Ther
    Huntgeburth M et al., 2011, The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart., Clin Res Cardiol
    Baudhuin LM et al., 2010, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure., Am J Cardiol
    Metra M et al., 2010, Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure., Cardiovasc Drugs Ther
    Chen L et al., 2007, Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol., Pharmacogenet Genomics
    Lobmeyer MT et al., 2007, Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure., Pharmacogenet Genomics
    Liu J et al., 2006, beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension., Clin Pharmacol Ther
    Terra SG et al., 2005, Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy., Pharmacogenet Genomics
    de Groote P et al., 2005, Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure., Pharmacogenet Genomics
    Terra SG et al., 2005, beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure., Clin Pharmacol Ther
    Liu et al., 2003, Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol., Clin. Pharmacol. Ther.
    Mialet Perez J et al., 2003, Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure., Nat Med
    White HL et al., 2003, An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study., Eur J Heart Fail
    Johnson et al., 2003, Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol., Clin. Pharmacol. Ther.
    O'Shaughnessy KM et al., 2000, The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects., Clin Sci (Lond)
    Sofowora GG et al., 2003, A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade., Clin Pharmacol Ther
    Alberti et al., 1997, Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists., J. Cardiovasc. Pharmacol.
    Schäfer et al., 2000, Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat., Am. J. Physiol., Cell Physiol.
    Brown et al., 2002, Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption., Eur. J. Pharmacol.
    Horinouchi et al., 2007, Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol., Life Sci.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Nuttall et al., 2003, A comparison of the beta1-selectivity of three beta1-selective beta-blockers., J Clin Pharm Ther
    Iaccarino G et al., 2005, beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene., Pharmacogenomics J
    Magvanjav O et al., 2017, Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials., J Am Heart Assoc
    Kurland L et al., 2004, Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial., Am J Hypertens
    Kurland L et al., 2001, Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients., J Hypertens
    Vandell AG et al., 2012, G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension., Hypertension
    Chang SW et al., 2018, Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes., Pharmacogenomics J
    Liljedahl et al., 2004, Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment., BMC Cardiovasc Disord
    Chen et al., 2006, [Effects of atenolol and metoprolol on cardiomyocyte apoptosis and related gene expression after acute myocardial infarction in rats]., Zhongguo Yi Xue Ke Xue Yuan Xue Bao
    Beitelshees AL et al., 2009, CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response., Circ Cardiovasc Genet
    Rimpelä JM et al., 2017, Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses., Pharmacogenomics
    Hallberg et al., 2004, Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)., Clin Cardiol
    Dudley C et al., 1996, Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes., J Hypertens
    Price ET et al., 2011, Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study., Pharmacogenet Genomics
    Hallberg P et al., 2004, Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)., Clin Cardiol
    Yeh et al., 2006, Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment., Am. J. Hypertens.
  • ATENOLOL   STN1

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • ATENOLOL   RRP1B

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • ATENOLOL   TBX2

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • ATENOLOL   ACY3

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28353407


    Sources:
    PharmGKB

  • ATENOLOL   PROX1

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   PLEKHH2

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27670767


    Sources:
    PharmGKB

  • ATENOLOL   ZMAT4

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   GALNT2

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   XIRP2

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   GRK4

    Interaction Score: 1.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22949529


    Sources:
    PharmGKB

  • ATENOLOL   ALDH1A2

    Interaction Score: 1.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29097388


    Sources:
    PharmGKB

  • ATENOLOL   SLC4A1

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   ADRB1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    2903243 22617224 21311897 20643254 20352314 20235788 18075464 17496726 16815314 15864115 15861037 15735607 14534524 14502278 12921807 12844134 11787477 12709726 9300315 10913016 12065078 17628611 11752352


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ATENOLOL   GJA1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16448880


    Sources:
    NCI

  • ATENOLOL   DPYS

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   SLC25A31

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   LRRC15

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   AGT

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14700505 11593098


    Sources:
    PharmGKB

  • ATENOLOL   FTO

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   EDN1

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15188945


    Sources:
    PharmGKB

  • ATENOLOL   GNB3

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20235788


    Sources:
    PharmGKB

  • ATENOLOL   LDLR

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15453913


    Sources:
    NCI PharmGKB

  • ATENOLOL   NR1H3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21562465


    Sources:
    PharmGKB

  • ATENOLOL   PTH

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2649632


    Sources:
    NCI

  • ATENOLOL   PLA2G4A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   PRKCB

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   ACE

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11593098 8728305 12844134


    Sources:
    PharmGKB

  • ATENOLOL   CACNA1C

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20031608


    Sources:
    PharmGKB

  • ATENOLOL   TGFB1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15049387


    Sources:
    NCI

  • ATENOLOL   BAX

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16995309


    Sources:
    NCI

  • ATENOLOL   ADRA2A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15614026


    Sources:
    PharmGKB

  • ATENOLOL   ADRB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    12795776 16027735


    Sources:
    PharmGKB

  • ATENOLOL   PTGS2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ATENOLOL   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: ATENOLOL

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class anti-arrhythmia agents
    Drug Class antihypertensive agents
    Year of Approval 1981

    Publications:

  • TdgClinicalTrial: ATENOLOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anti-Arrhythmia Agents
    Drug Indications Antihypertensive Agents
    Drug Class small molecule

    Publications:

  • NCI: ATENOLOL

    • Version: 14-September-2017

    Alternate Names:
    C28836 NCI drug code

    Drug Info:

    Publications:
    Chen et al., 2006, [Effects of atenolol and metoprolol on cardiomyocyte apoptosis and related gene expression after acute myocardial infarction in rats]., Zhongguo Yi Xue Ke Xue Yuan Xue Bao
    Hallberg et al., 2004, Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)., Clin Cardiol
    Liljedahl et al., 2004, Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment., BMC Cardiovasc Disord

  • DTC: ATENOLOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL24 ChEMBL Drug ID

    Drug Info:

    Publications:
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem

  • PharmGKB: atenolol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Iniesta R et al., 2019, Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals., Hypertension
    Magvanjav O et al., 2017, Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials., J Am Heart Assoc
    Chang SW et al., 2018, Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes., Pharmacogenomics J

  • TTD: Atenolol

    • Version: 2020.06.01

    Alternate Names:
    D01UXC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL24

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL24

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21